Furthermore, recent studies (52, 53) have demonstrated long-term benefits of semaglutide on CV outcomes, reinforcing the concept that GLP-1 receptor agonists may reduce the burden of CV outcomes in patients with T2D beyond mere glycemic control. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.